Lutetium Lu-177 Vipivotide Tetraxetan vs Trastuzumab
Lutetium Lu-177 Vipivotide Tetraxetan vs Trastuzumab: Overview
This comparison examines the pharmacological differences between Lutetium Lu-177 Vipivotide Tetraxetan and Trastuzumab.
Mechanism of Action
Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.
Pharmacokinetics
Half-life: Trastuzumab — 28 days.
Chemical Properties
Type: Lutetium Lu-177 Vipivotide Tetraxetan — Protein; Trastuzumab — Antibody.